الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 81 |  |  |
| | | from | 81 | | |
Abstract
Prostate cancer is the fourth most common malignancy in males worldwide. Bone metastases are highly prevalent in patients with advanced metastatic prostate cancer. Bone metastases occur in up to 84% of patients with metastatic prostate cancer and frequently represent the only site of metastatic disease.
Evaluation of tumor response in patients with bone only metastatic disease relies solely on decrease in prostate-specific antigen (PSA) level, which has not been proven to be a surrogate for improved survival. There is an urgent unmet need to identify, develop, and validate noninvasive response biomarkers for bone metastases in prostate cancer.
The aim of this study is to determine the usefulness of DWI for the assessment of response of bone metastases to hormonal treatment in patients with advanced metastatic prostate cancer.
This study was conducted on 10 patients with prostate cancer and bone metastasis referred to the radio-diagnosis department of Alexandria university hospitals.
The pre-treatment range of ADC for all our patients lesions was (0.19 - 0.93) and the pretreatment mean ADC for all the studied patients lesions was (0.62 ±0.11) in relation to the mean pre-treatment PSA level (313.31± 461.10).
In the pre-treatment MRI examination, all the examined osseous deposits in all patients showed diffusion restriction (< 1x10-3mm2/sec). All the patients also had high PSA levels.
The post-treatment range of ADC for all our patients studied bony lesions was (0.55 - 1.6) and the post treatment mean ADC for all the studied patients lesions was (1.18±0.28) in relation to the mean post-treatment PSA level (25.47 ± 48.57).
Eight out of the ten patients included in our study showed increase in the mean ADC values (>1x10-3mm2/sec) and a parallel decline in the PSA levels after 12 weeks of the start of the hormonal treatment.
The other two patients showed that their bony metastatic lesions still have low mean ADC value (< 1x10-3mm2/sec) and high PSA levels.
The Pearson correlation coefficient was calculated across times to delineate the relationship between serum PSA level and the averaged mean ADC in each patient. For this purpose, the averaged mean ADC was calculated as a weighted mean according to each patient. Correlation showed a significant negative relationship between PSA values and mean ADCs per patient.
The results in this study revealed that the ADC range can be used in detecting the response of bone metastatic lesions in patients of prostate cancer.